Compare Revvity Inc (RVTY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard S&P 500 ETF — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Vanguard S&P 500 ETF trades at $715.76 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 106× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Vanguard S&P 500 ETF for 55 Days on average.
| RVTY | VOO | |
|---|---|---|
Market Cap | $16.98B | $1.80T |
Volume | 1,456,900 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $157.36 | $716.17 |
52-Week Low | $82.26 | $580.93 |
Typical Hold Time | 12 Days | 55 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
VOO trades at $715.68, up 0.18% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building despite short interest increasing 46.9% in September. Dividend yield remains modest with the next payment scheduled for September 30, 2026.
Outlook remains positive given S&P 500 exposure and historical resilience, though risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated short interest. The ETF's low-cost structure and diversification provide stability amid market volatility, making it suitable for core portfolio holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
